Patients with risk of sarcopenia were significantly younger and shorter than patients without risk of sarcopenia (Group A vs. Group B, age: 13.9 ± 2.8 years vs. 16.4 ± 1.9 years, p < 0.05; height Z score: 0.7 ± 1.1 vs. 0.4 ± 1.0, p < 0.05, respectively) at the initiation of anti-TNF therapy. Here, TNF is linked to sarcopenia.